Privia Health Group, Inc.

How big is Privia Health Group, Inc.?

As of Jun 18, Privia Health Group, Inc. has a market capitalization of $2.73 billion, with net sales of $1.80 billion and a net profit of $20.04 million for the latest four quarters. Shareholder's funds were $635.18 million, and total assets amounted to $1.15 billion as of December 2024.

As of Jun 18, Privia Health Group, Inc. has a market capitalization of 2,729.78 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1,801.25 million and a net profit of 20.04 million for the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024.<BR><BR>As of December 2024, the company's shareholder's funds were 635.18 million, and total assets amounted to 1,145.78 million.

What does Privia Health Group, Inc. do?

Privia Health Group, Inc. is a small-cap company in the insurance industry, reporting net sales of $480 million and a net profit of $6 million as of March 2025. Key metrics include a P/E ratio of 181.00 and a market cap of approximately $2.73 billion.

Overview:<BR>Privia Health Group, Inc. operates in the insurance industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 480 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 6 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,729.78 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 181.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -999,999.00 <BR>Return on Equity: 2.37% <BR>Price to Book: 4.14 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Privia Health Group, Inc.?

Is Privia Health Group, Inc. technically bullish or bearish?

As of September 19, 2025, Privia Health Group, Inc. shows a neutral technical trend with mixed indicators, having outperformed the S&P 500 recently but significantly underperformed over the last three years.

As of 19 September 2025, the technical trend for Privia Health Group, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands also show bullish conditions on the weekly and mildly bullish on the monthly. However, daily moving averages indicate a mildly bearish trend, and the weekly OBV shows no trend, while the monthly OBV is mildly bearish. The KST is mildly bullish on the weekly and bullish on the monthly, and Dow Theory indicates no trend on the weekly but mildly bullish on the monthly.<BR><BR>In terms of performance, Privia Health has outperformed the S&P 500 over the past week, month, year-to-date, and year, but significantly underperformed over the last three years.

Is Privia Health Group, Inc. overvalued or undervalued?

As of October 24, 2025, Privia Health Group, Inc. is considered overvalued with a high P/E ratio of 181 and other premium valuation metrics, despite a strong year-to-date return of 32.94%, but it has underperformed over three years with a return of -19.34% compared to the S&P 500.

As of 24 October 2025, the valuation grade for Privia Health Group, Inc. moved from very expensive to fair. The company appears to be overvalued, particularly when considering its P/E ratio of 181, which is significantly higher than peers like Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59. Additionally, the EV to EBITDA ratio of 82.17 and the Price to Book Value of 4.29 further highlight the premium at which Privia is trading compared to its industry counterparts.<BR><BR>In terms of performance, Privia Health Group has shown strong returns, with a year-to-date return of 32.94%, significantly outperforming the S&P 500's 15.47%. However, over the three-year period, the company has underperformed with a return of -19.34% compared to the S&P 500's 78.85%. This mixed performance, alongside its high valuation ratios, suggests that while the stock may have short-term appeal, it is fundamentally overvalued in the context of its financial metrics.